Dutch biotech Laigo Bio has launched with 11.5 million euros ($12.7 million) in seed financing to progress its SureTAC ...

This important study describes a deep learning framework that analyzes single-cell RNA data to identify a tumor-agnostic gene signature associated with brain metastases. The identified signature ...

Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...

Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism. Learn why SMMT stock is a Buy.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

Mechanistic insights into VEGF(R) inhibitor-associated arthritis offer promising avenues for developing potential therapeutic strategies to mitigate this treatment side effect and improve the quality ...

Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

Absent tools such as rebate reform, transparent pricing or accelerated biosimilar substitution, true price competition will ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistan ...

AstraZeneca AZN and Merck MRK are both major global pharmaceutical companies with diversified drug portfolios. While Merck is ...